More recently, the GLP-1 / gastric inhibitory polypeptide (GIP) receptor co-agonist tirzepatide (at doses of 5, 10, and 15 mg) was approved for obesity therapy in the UK. This evidence concerns the gene GLP1R and obesity disorder.